Monocyte suppressing action of fenofibrate.
Journal Title: Pharmacological Reports - Year 2005, Vol 57, Issue 3
Abstract
Since atherosclerosis has been proven to be an inflammatory disease, itis obvious that the proper treatment for dyslipidemia should not only correct lipid parameters but alsoinhibit inflammation. Monocytes and monocyte-derived proinflammatory cytokines are widely known to beinvolved in the formation and rupture of the atherosclerotic plaque. The aim of our study was to assessthe effect of fenofibrate, a commonly used hypolipidemic drug, on the release of interleukin 1beta (IL-1beta),interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) by monocytes from patients with combinedhyperlipidemia. Fourteen patients with biochemically confirmed type IIb dyslipidemia who did not respondto a low-fat diet were treated with micronized fenofibrate for 1 month. The control group included 12healthy, normolipidemic, age-matched subjects. To accurately evaluate the levels of the inflammatorycytokines, we excluded patients with any inflammatory disease. Monocytes were isolated from peripheralblood before and after the treatment. IL-1beta, IL-6 and MCP-1 release was measured by enzyme-linkedimmunosorbent assay (ELISA) after lipopolysaccharide stimulation. IL-1beta, IL-6 and MCP-1 levels weresignificantly higher in hyperlipidemic patients compared to the control (143.9 +/- 6.5 vs. 74.4 +/- 4.4pg/ml; 8212 +/- 285 vs. 6110 +/- 170 pg/ml; 19.6 +/- 0.9 vs. 12.3 +/- 0.6 ng/ml, respectively). Thirty-dayfenofibrate treatment decreased the release of IL-1beta by 43% (143.9 +/- 6.5 vs. 86.2 +/- 5.9 pg/ml),of IL-6 by 22% (8212 +/- 285 vs. 6330 +/- 234 pg/ml), and of MCP-1 by 29% (19.6 +/- 0.9 vs. 14.0 +/-0.8 ng/ml). The evaluated cytokines were markedly elevated in patients with type IIb dyslipidemia. Effectivefenofibrate therapy had a significant inhibitory effect on the release of monocyte-derived inflammatorycytokines.
Authors and Affiliations
Bogusław Okopień, Jan Kowalski, Robert Krysiak, Krzysztof Łabuzek, Aldona Stachura-Kułach, Andrzej Kułach, Marek Zieliński, Zbigniew Herman
Keywords
Related Articles
- EP ID EP159747
- DOI -
- Views 108
- Downloads 0
Influence of ezetimibe on ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
Background: We evaluated effect of ezetimibe on selected parameters determining NO level in rat liver subjected to ischemia reperfusion (IR). Methods: Rats received ezetimibe (5 mg/kg) (groups E0 and EIR) or saline solut...
Effect of NMDA receptor antagonists on behavioral impairment induced by chronic treatment with dexamethasone.
Severe and prolonged stress but also long-term treatment with glucocorticoids (GCs) have been described to cause brain damage (especially hippocampal and striatal neurons) in humans as well as in animals. GCs potentiate...
Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats.
It has been proposed that metformin exerts protective effects on ischemic hearts. In the present study, we evaluated the effects of metformin on cardiac function, hemodynamic parameters, and histopathological changes in...
Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF).
Brain-derived neurotrophic factor (BDNF) is a key neurotrophic factor in the brain. It plays an important role in the etiopathogenesis and pharmacotherapy of mental disorders, such as depression or schizophrenia. In rece...
Inhibition of Wnt/β-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells.
Background: Ursolic acid, a pentacyclic triterpenoid, is known to exert antitumor activity in breast, lung, liver and colon cancers. Nonetheless, the underlying mechanism of ursolic acid in prostate cancer cells still re...